RELIEF THERAPEUTICS Holding ( (CH:RLF) ) has shared an update.
Relief Therapeutics has released its 2024 financial results and corporate update, highlighting significant operational achievements and a stronger financial position. The company has made progress in its core pipeline, particularly with its next-generation liquid sapropterin formulation for phenylketonuria and a proprietary hypochlorous acid solution for epidermolysis bullosa. Relief looks forward to achieving important clinical and regulatory milestones in 2025, which could enhance its industry positioning and stakeholder value.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, Switzerland. The company focuses on advancing treatment paradigms for rare and debilitating diseases, with expertise in drug delivery systems and drug repurposing. Relief’s clinical pipeline targets unmet medical needs in rare dermatological, metabolic, and respiratory conditions, and it has successfully brought several approved products to market through licensing and distribution partnerships.
YTD Price Performance: -46.08%
Average Trading Volume: 1,873
Technical Sentiment Signal: Strong Buy
Current Market Cap: $30.82M
Learn more about RLF stock on TipRanks’ Stock Analysis page.